Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 18/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 13/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 9/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832990 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017367 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017369 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL192857 | 0.96 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017372 | 0.96 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL14515933 | 0.96 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017366 | 0.95 | LPAR3 (0.90) | LPAR3LPAR2LPAR1 | |
| SCHEMBL31060667 | 0.89 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL193156 | 0.89 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL14515931 | 0.89 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089986-B1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | RXBIO INC (US) | 2019-06-26 | — | — | EP | claimed |
| US-20170226139-A1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | RXBIO INC (US) | 2017-08-10 | — | — | US | claimed |
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | claimed |
| US-9567288-B2 | Crystalline salts of (Z)-O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate | RXBIO, INC. (US) | 2017-02-14 | — | — | US | claimed |
| EP-3089986-A1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | Rxbio Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015102856-A1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | RXBIO INC. (US) | 2015-07-09 | — | — | WO | claimed |
| US-20150183726-A1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | RXBIO INC (US) | 2015-07-02 | — | — | US | claimed |
| US-20120270780-A1 | METHOD AND COMPOSITION FOR MODULATING ERYTHROPOIESIS | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-10-25 | — | — | US | claimed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | claimed |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2008-04-17 | — | — | US | claimed |
| EP-1906972-A2 | LPA2 RECEPTOR AGONIST INHIBITORS OF CFTR | The University of Tennessee Research Foundation (US) | 2008-04-09 | — | — | EP | claimed |
| US-7217704-B2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-15 | — | — | US | claimed |
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070078111-A1 | LPA2 receptor agonist inhibitors of CFTR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-04-05 | — | — | US | claimed |
| JP-2007508324-A | — | — | 2007-04-05 | — | — | JP | claimed |
| WO-2007011905-A2 | LPA2 RECEPTOR AGONIST INHIBITORS OF CFTR | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-25 | — | — | WO | claimed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | claimed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226139-A1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | PHYKPL, OSGEP, ZYX | LPAR3 740/4885LPAR2 919/4885LPAR1 550/4885 |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
| US-20150183726-A1 | CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE | PHYKPL, OSGEP, ZYX | LPAR3 740/4885LPAR2 919/4885LPAR1 550/4885 |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR4, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
| US-20070078111-A1 | LPA2 receptor agonist inhibitors of CFTR | LPAR2, NHERF1, LPAR1 | LPAR3 6/4885LPAR2 1/4885LPAR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.